AIDS 2004; Bangkok, Thailand; July 11-16, 2004

Key Links:

By Topic:


See Also
A dual-NRTI backbone for multiple patients >

UNBP3028 1/17

The Body PRO Covers: The XV International AIDS Conference

Non-Hodgkin's Lymphoma Rates Lower in HAART-Treated Patients

July 12, 2004


Untreated HIV infection confers a huge increase in the incidence of non-Hodgkin's lymphoma (NHL). Understanding the extent to which HAART mitigates this risk is of vital importance to HIV-infected persons.

Details of This Study

Waterson et al report on a 9,621-person cohort assembled at London's Chelsea & Westminister Hospital. Over the entire span of the cohort's observation, 280 patients were diagnosed with lymphoma (206 with systemic NHL, 55 with primary cerebral lymphoma, and 19 with Hodgkin's lymphoma). During the 1996-2003 interval, 102 of 5,832 persons were diagnosed with lymphoma. Multivariate analysis found decreased age, higher nadir CD4+ and CD8+ counts and exposure to HAART to be associated with lower NHL incidence rates.

Non-Hodgkin's Lymphoma Rates Lower in HAART-Treated Patients

Significance for Patients/Clinicians

This study provides a good basis for the very encouraging belief that today's HAART regimens will be protective against NHL.

Complete Index

Tell us what you think of The Body's conference coverage!


Abstract: Anti-Retroviral Treatment Regimens and the Prevention of Systemic HIV-Related Non-Hodgkin's Lymphoma (Poster MoPeB3257)
Authored by: A Waterston, J Stebbing, C Thirlwell, T Newson-Davis, S Mandalia, M Nelson, B G Gazzard, M Bower

This article was provided by TheBodyPRO. It is a part of the publication The XV International AIDS Conference.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.